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Factor V Leiden Is Associated with Higher Risk of Deep Venous 
Thrombosis of Large Blood Vessels
Aim To determine the prevalence of factor V Leiden mutation in pa-
tients with different presentation of venous thromboembolic disease 
and healthy individuals in the Republic of Macedonia.
Methods The retrospective case control study involved 190 patients 
with venous thromboembolic disease and 200 healthy individuals, who 
were screened for the presence of factor V Leiden mutation, using a 
polymerase chain reaction-restriction fragment length polymorphism 
method. The prevalence of factor V Leiden was analyzed according to 
the localization of thrombosis, presence of risk factors, and family his-
tory of thrombosis. The odds of deep venous thrombosis were calcu-
lated with respect to the presence of factor V Leiden mutation.
Results The prevalence of factor V Leiden mutation among patients 
with venous thromboembolic disease was 21.1%, compared with 5.5% 
in the healthy individuals. Factor V Leiden positive patients had the 
first episode of deep venous thrombosis at a younger age, and the prev-
alence of the mutation was the highest among patients with a posi-
tive family history of thrombosis (33.9%, P = 0.003) and in patients 
with deep venous thrombosis affecting a large blood vessel (37.7%, 
P = 0.001). The prevalence of factor V Leiden mutation was lower in 
patients with calf deep venous thrombosis and primary thromboembo-
lism (13.3% and 13.1%, respectively; P>0.05). The odds ratio for ilio-
femoral or femoral deep venous thrombosis in factor V Leiden carriers 
was 10.4 (95% confidence interval, 4.7-23.1).
Conclusion The prevalence of factor V Leiden mutation was high in 
patients with venous thromboembolic disease and healthy individuals 
in the Republic of Macedonia. Factor V Leiden carriers have the high-
est odds of developing deep venous thrombosis affecting a large venous 
blood vessel.
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Factor V Leiden mutation has been recognized 
as the most prevalent genetic risk factor for ve-
nous thromboembolic disease (1-7). Single nu-
cleotide substitution (G1691A) in factor V gene 
leads to an amino acid substitution, Arg506Gln, 
in factor V molecule, disrupting the cleavage site 
recognized by activated protein C (3). Activated 
protein C is a natural anticoagulation molecule, 
which acts by cleaving the molecule of activated 
factor V, thus limiting its procoagulation activ-
ity. The prolonged half-life and procoagulation 
activity of the activated factor V cause increased 
thrombotic tendency in patients carrying even a 
single copy of the mutated gene (4-7).
It has been estimated that the prevalence of 
factor V Leiden among patients with deep ve-
nous thrombosis varies between 20% and 30% 
(8). Based on these data, it has been proposed 
that heterozygous carriers have 7-fold and ho-
mozygotes 80-fold higher risk of deep venous 
thrombosis (8). Factor V Leiden prevalence is 
lower in patients with pulmonary thromboem-
bolism – only 7-9% (3,9,10). Several studies have 
shown that factor V Leiden mutation is associ-
ated with an increased risk for recurrent throm-
botic episodes, justifying screening patients with 
deep venous thrombosis for factor V Leiden (11-
13). Women carriers of factor V Leiden are at a 
higher risk of obstetric complications, such as ec-
lampsia, pre-eclampsia, abruption of the placen-
ta, recurrent abortions, and intrauterine retarda-
tion of the fetal growth (14-16).
The frequency of factor V Leiden mutation 
in the studied healthy populations varies from 
3% to 12% in Europe (17,18) and from 1% to 
6% in North America (19), and it is almost ab-
sent in the indigenous populations in Africa and 
Australasia (17,20).
The aim of this study was to determine the 
prevalence of factor V Leiden mutation in pa-
tients with venous thromboembolic disease and 
healthy individuals in the Republic of Macedo-
nia and to compare the findings with the pub-
lished data for other countries in the region. 
We also analyzed the differences in the preva-
lence of factor V Leiden mutation with respect 
to the clinical presentation of the venous throm-
boembolic disease (deep venous thrombosis or 
primary thromboembolism), age, sex, presence 




The retrospective case-control study includ-
ed 190 consecutive patients with pulmonary 
thromboembolic disease hospitalized at the De-
partment of Hematology or referred for nuclear 
medicine diagnostics to the Institute of Patho-
physiology and Nuclear Medicine, Skopje Uni-
versity Hospital, Macedonia. There were 114 
women aged 40 ± 15 years (mean±standard de-
viation) and 76 men aged 45 ± 14 years. The di-
agnosis of venous thromboembolic disease was 
based on patient’s history, clinical findings, ra-
dioisotope venography, and ventilation/perfu-
sion scintigraphy. In some cases, additional di-
agnostic procedures, such as ultrasound and 
D-dimer testing, were also used. An acquired risk 
factor for deep venous thrombosis was identified 
in nearly half of the patients (66 of 114 women 
and 33 of 76 men). The most frequent acquired 
risk factors in women were pregnancy and de-
livery (44 of 114) and surgical procedure (12 of 
114), whereas surgical procedure (18 of 76) and 
trauma (10 of 76) were the most frequent in 
men. Family history of thromboembolic disease 
was present in 75 of 114 women and 53 of 76 
men. Patients were divided into 3 groups accord-
ing to the deep venous thrombosis localization: 
patients with iliofemoral or femoral thrombosis 
(n = 61), calf thrombosis (n = 84), and primary 
thromboembolism (n = 45). The control group 
consisted of 200 randomly selected, age and sex 
non-matched healthy individuals (120 women 
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and 80 men, 130 Macedonian and 70 Albanian 
DNA samples).
All patients and healthy individuals signed a 
written consent to participate in the study, which 
was approved by the Committee of the Tempus-
Phare postgraduate program.
Venography and ventilation/perfusion 
scintigraphy
The assignment of patients into one of the study 
groups according to localization of thrombo-
sis was based on clinical findings, combined ra-
dionuclide flow venogram, and perfusion/ven-
tilation radioisotope findings. Deep venous 
thrombosis was diagnosed by radionuclide flow 
venogram obtained after a simultaneous injec-
tion of 110-150MBq 99mTc-labeled macro-ag-
gregates of albumin (99mTc-MAA) into superfi-
cial foot veins. The bolus of injected radioactivity 
was followed through the deep venous system, 
as tourniquets were applied above the ankle and 
below the knee, with a large field of view gamma 
camera. Deep venous thrombosis was diagnosed 
in cases of reduced speed of passage of the bolus, 
incompletely filled deep vessels, and lack of visu-
alization of the deep venous system with present 
collateral flow due to a complete blood flow ob-
struction. The lung perfusion study was carried 
out following the acquisition of the radionuclide 
flow venogram (static equilibrium acquisition in 
4 standard positions). The diagnosis of pulmo-
nary thromboembolism was based on the com-
bination of perfusion defects, which are almost 
completely filled with 99mTc-DTPA aerosols in 
the ventilation radionuclide study according to 
the PIOPED criteria for high probability of pul-
monary thromboembolism (21).
Factor V Leiden mutation analysis
Genomic DNA was isolated from peripheral 
blood leucocytes by using standard SDS-protein-
ase K digestion and phenol-chloroform extrac-
tion protocol (22). Factor V Leiden mutation 
was detected using polymerase chain reaction 
(PCR) restriction fragment length polymor-
phism method (3). Briefly, the region flanking 
the mutation was amplified by PCR (forward 
primer CCC AGT GCT TAA CAA GAC CA, 
reverse primer TGT TAT CAC ACT GGT 
GCT AA) and the PCR product digested with 
the restriction enzyme MnlI (New England Bi-
olabs, Ipswich, MA, USA). The products from 
the digestion were separated on a 3% agarose gel, 
stained with ethidium bromide and visualized on 
a UV transilluminator.
Statistical analysis
Factor V Leiden prevalence results are presented 
as proportions (carrier and allele frequencies) and 
95% confidence interval (CI). The differences in 
the distribution of Factor V Leiden mutation 
were analyzed with χ2 test, and the differences in 
age were analyzed with t test with StatGraphics 
for Windows 5.0. P<0.05 was considered statisti-
cally significant. Odds ratios (OR) with 95% CI 
were calculated to estimate risk of thromboembo-
lism (http://www.hutchon.net/ConfidOR.htm).
Results
Among 190 patients with venous thromboem-
bolic disease, 2 were factor V Leiden homozy-
gotes and 38 were factor V Leiden carriers. Thus, 
the overall prevalence of factor V Leiden was 
21% (95% CI, 14.3-25.7) and the overall factor 
V Leiden allele frequency was 11.1% (7.9-14.3). 
Only 11 carriers were identified among 200 
healthy individuals. Thus, in the general pop-
ulation in Macedonia, factor V Leiden preva-
lence was 5.5% (2.3-8.7) and allele frequency was 
2.8% (1.2-4.4). Factor V Leiden prevalence was 
somewhat higher among Macedonians (6.9%; 
2.5-11.3) than among Albanians (2.9%; 0-6.8) 
(Table 1). The odds ratio for venous thrombo-
embolic disease was 4.6 (2.3-9.2) in factor V 
Leiden carriers.
Two factor V Leiden homozygotes and 21 
carriers were identified in the group of patients 
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with iliofemoral or femoral thrombosis, with the 
prevalence of factor V Leiden mutation of 37.7% 
(25.5-49.8) and factor V Leiden allele frequency 
of 20.5% (13.3-27.7). The odds ratio for iliofem-
oral or femoral deep venous thrombosis was 10.4 
(4.7-23.1) in factor V Leiden carriers (Table 1).
The prevalence of the mutation in the group 
of patients with deep venous thrombosis of the 
calf was 13.1% (5.9-20.3). Factor V Leiden allele 
frequency in this patient group was 6.6% (3.1-
10.1) and the OR for calf thrombosis in factor V 
Leiden carriers was 2.6 (1.1-6.2) (Table 1).
In the group of patients with primary throm-
boembolism, factor V Leiden prevalence was 
13.3% (2.3-23.2) and the odds ratio for prima-
ry thromboembolism in factor V Leiden carriers 
was 2.6 (0.9-7.6) (Table 1).
Distribution of factor V Leiden mutation
There was no difference in the prevalence of the 
mutation between men and women with venous 
thromboembolic disease (19.9% vs 23.7%, re-
spectively; P = 0.468) (Table 2). The analysis of 
the age of the first thrombotic event was carried 
out in 100 patients with deep venous thrombo-
sis in whom the age of the first thrombotic event 
could be unambiguously determined (Table 2). 
The mean age of first deep venous thrombosis 
was 33.7 ± 11.5 years for factor V Leiden positive 
and 41.1 ± 15.7 years for factor V Leiden nega-
tive patients (P = 0.033). Such a difference was 
not found in the group of patients with primary 
thromboembolism.
Overall, patients with family history of 
thromboembolism had a higher prevalence of 
factor V Leiden compared with the patients 
without family history of thromboembolism 
(33.9% vs 14.8%, respectively; P = 0.003) (Table 
2). Whereas patients with deep venous throm-
bosis and positive family history had higher prev-
alence of factor V Leiden than the ones without 
positive family history (44.4% vs 14.1%, respec-
tively; P = 0.001), factor V Leiden prevalence was 
not significantly different in patients with prima-
ry pulmonary thromboembolism with respect 
to the presence of family history of thrombosis 
(11.1% vs 13.9%, respectively; P = 0.782). There 
was no difference in the prevalence of factor V 
Leiden between the groups of patients with and 
without additional acquired risk factor (Table 
2). The prevalence of factor V Leiden muta-
Table 1. Prevalence of factor V Leiden in patients with venous thromboembolic disease and healthy individuals in the Republic of 
Macedonia
No. (%) of subjects*
 total A/G or A/A G/G OR (95% CI)†
Patients with venous thromboembolic disease: 190 40 (21.1) 150 (78.9)  4.6 (2.3-9.2)
 deep venous thrombosis 145 34 (23.5) 111 (76.5)  5.3 (2.6-10.8)
 iliofemoral deep venous thrombosis  61 23 (37.7)  38 (62.3) 10.4 (4.7-23.1)
 calf deep venous thrombosis  84 11 (13.1)  73 (86.9)  2.6 (1.1-6.2)
 primary pulmonary thromboembolism  45  6 (13.3)  33 (86.7)  2.6 (0.9-7.6)
Healthy controls: 200 11 (5.5) 189 (94.5)
 Macedonians 130  9 (6.9) 121 (93.1)
 Albanians  70  2 (2.9)  68 (97.1)
*A/G – factor V Leiden carrier, A/A – factor V Leiden homozygote, G/G – normal.
†Odds ratio (OR) with 95% confidence interval (CI) for development of venous thromboembolic disease in carriers of factor V Leiden mutation calculated relative to factor V Leiden 
prevalence in the group of healthy subjects.
Table 2. Prevalence of factor V Leiden with respect to age, sex, 
presence of acquired risk factor, and family history of venous 
thromboembolism*
No. (%) of subjects
Parameter total A/G or A/A G/G P
Age:
 DVT (years; mean±SD) 100 25 (33.7 ± 11.5)  75 (41.1 ± 15.7) 0.033
 PTE (years; mean±SD)  45  6 (45.3 ± 8.9)  39 (46.1 ± 11.5) 0.872
Sex:
 men  76 18 (23.7)  58 (76.3) 0.468
 women 114 22 (19.9)  92 (80.1)
Acquired risk factor:
 absent  91 20 (22.0)  71 (78.0) 0.764
 present  99 20 (20.2)  79 (79.8)
 pregnancy or delivery  44  8 (18.2)  36 (71.8)
Family history of VTE:
 positive  62 21 (33.9)  41 (66.1) 0.003
 negative 128 19 (14.8) 109 (85.2)
*Abbreviations: A/G – factor V Leiden carrier, A/A – factor V Leiden homozygote, G/G 
– normal, DVT – deep venous thrombosis, PTE – primary thromboembolism, VTE 
– venous thromboembolic disease.
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tion in the group of women with deep venous 
thrombosis related to pregnancy and delivery 
was 20.5% (8 carriers and 1 homozygote), and 
nearly twice higher among the women with 
family history of thrombosis (26.1% vs 14.3%) 
(Table 2).
Discussion
We found a high prevalence of factor V Leiden 
mutation in the general population in the Re-
public of Macedonia. This finding is consistent 
with the reported prevalence for other countries 
in the region, such as Greece, Bulgaria, Serbia, 
and Croatia (23-26) (Table 3). We found that 
the overall prevalence of factor V Leiden in pa-
tients with venous thromboembolic disease was 
21%, increasing the odds for venous thrombo-
embolism in factor V Leiden carriers to 4.6. Our 
finding of low prevalence of factor V Leiden in 
patients with primary pulmonary thromboem-
bolism (13.1%), increasing the odds ratio to only 
2.3 in factor V Leiden carriers, confirms previ-
ously published data (3,6,10).
Given the well established association be-
tween factor V Leiden mutation and obstet-
ric complications, we analyzed its prevalence in 
women with deep venous thrombosis during 
pregnancy or within the first few weeks after de-
livery. We found that one in 5 women in this 
group were factor V Leiden carriers. These find-
ings strongly support the idea of systemic screen-
ing for factor V Leiden mutation in the popu-
lation of women with deep venous thrombosis 
related to pregnancy and delivery, as this infor-
mation may be important in the adequate man-
agement of subsequent pregnancies.
There was a 3-fold higher prevalence of factor 
V Leiden mutation in patients with thrombo-
sis affecting the iliofemoral or femoral vein com-
pared with those with calf thrombosis. In other 
words, our results show that factor V Leiden car-
riers are at higher risk of developing deep venous 
thrombosis affecting a large venous blood vessel 
compared with thrombosis affecting calf veins or 
primary pulmonary thromboembolism. A study 
by Björgell et al (30) on the localization of the 
thrombotic process in factor V Leiden carriers 
indicated the opposite. In their study, the preva-
lence of factor V Leiden was significantly higher 
in patients with deep venous thrombosis local-
ized below the iliofemoral segment. Other stud-
ies dealing with larger number of cases with prox-
imal deep venous thrombosis localization have 
shown that the prevalence of factor V Leiden in 
these patients was markedly higher (13,28,31). 
These differences in the prevalence of factor V 
Leiden in patients with proximal deep venous 
thrombosis may be due to the differences in the 
selection and diagnostic criteria used in the dif-
ferent studies. Alternative explanation could be 
the different relative contribution of factor V 
Leiden mutation in the context of the complex 
interplay of other coagulation defects and alleles 
in populations from different geographical re-
gions.
In conclusion, the prevalence of factor V 
Leiden mutation in the healthy population of 
Table 3. Prevalence of Factor V Leiden mutation in different populations in European countries
No. (%) of subjects
patients with venous thromboembolic disease general population
Population (ref. No.) total factor V Leiden mutation (%) total factor V Leiden mutation (%)
Greece (23) 172 55 (31.9) 104  5 (4.8)
Italy (27) 111 15 (15.3) 121  5 (4.1)
France (28) 165 24 (14.5) 200  7 (3.5)
UK (29) 471 96 (20.4) 511 15 (2.9)
The Netherlands (8) 471 92 (19.5) 474 14 (3.0)
Croatia (24) 160 33 (21.0) 155  6 (4.0)
Serbia (25) 175 52 (29.3) 120  7 (5.8)
Bulgaria (26) 128 32 (25.0) 100  9 (9.0)
Macedonia (this study) 190 40 (21.1) 200 11 (5.5)
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the Republic of Macedonia is similar to previ-
ously reported high prevalence of this mutation 
in other populations in the region. In addition, 
our results suggest that factor V Leiden carriers 
have the highest risk of developing deep venous 
thrombosis affecting larger venous blood ves-
sel, such as iliofemoral or femoral vein, and that 
routine factor V Leiden screening should be car-
ried out in patients who experience the first epi-
sode of deep venous thrombosis at younger age, 
especially if there is a positive family history of 
thrombosis and deep venous thrombosis related 
to pregnancy and delivery.
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